PTXOC
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Prescient Therapeutics Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
1
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Prescient Therapeutics Limited - Option Expiring 31-Mar-2023
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.03
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in PTXOC
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
177 weeks
💵 Average investment amount
$2,000
⏰ Last time a customer invested in PTXOC
958 days
PTXOC investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in PTXOC also invest in...
ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.
🙌 Performance (5Yr p.a)
9.81%
📊 Share price
$34.98 AUD
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
🌏 GLOBAL
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
14.08%
📊 Share price
$127.76 AUD
🌏 GLOBAL
⛳️ DIVERSIFIED
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
FAIR.AX was created on 2017-11-27 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes Australian companies that have passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
🙌 Performance (5Yr p.a)
6.01%
📊 Share price
$20.16 AUD
⛳️ DIVERSIFIED
VHY.AX was created on 2011-05-23 by Vanguard. The fund's investment portfolio concentrates primarily on high dividend yield equity. Vanguard Australian Shares High Yield ETF seeks to track the return of the FTSE Australia High Dividend Yield Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
11.50%
📊 Share price
$70.33 AUD
🇦🇺 AUSTRALIA
💸 FINANCIALS
⛳️ DIVERSIFIED
💰 HIGH DIVIDEND
📈 HIGH PRICE GROWTH
🧱 MATERIALS
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
🙌 Performance (5Yr p.a)
9.08%
📊 Share price
$14.51 AUD
🤖 TECHNOLOGY
⛳️ DIVERSIFIED
💸 FINANCIALS
📈 HIGH PRICE GROWTH
🌏 GLOBAL
Want more shares? Try these...
Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The company is also focused on developing therapies for a range of cancers, using CAR-T and targeted therapy approaches. The firm has a broad pipeline of cancer treatments, comprising CAR-T and targeted therapies, for cancers. Its product pipeline includes OmniCAR, PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. PTX-100 is a Phase Ib clinical candidate that block the cancer growth enzyme known as geranylgeranyl transferase-1. PTX-100 is in a pharmacokinetic basket study of hematological and solid malignancies, focusing on cancers with Ras and RhoA mutations. PTX-200 is in Phase Ib/IIa clinical candidate. PTX-200 is a novel PH domain inhibitor that inhibits an important tumor survival pathway known as Akt.